drugset / Trial / NCT07166263

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

NCT07166263

Phase 0 Not yet recruiting 15 enrolled Base Therapeutics (Shanghai) Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and intraperitoneal perfusion therapy. The safety and efficacy of this treatment will be evaluated.

Timeline

Start
2025-11
Primary completion
2027-06
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject NK510 Cell therapy Intravenous